ReviewAmerican journal of clinical and experimental urology2025
Efficacy of temsirolimus versus pazopanib in the treatment of advanced renal cell carcinoma: a meta-analysis.
Review in American journal of clinical and experimental urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTemsirolimus and pazopanib serve as first-line therapies for renal cell carcinoma (RCC). This meta-analysis was performed to assess and compare their efficacy, optimal treatment targets, and associated toxicities.
methodsWe searched the PubMed, CNKI, Wanfang, and VIP databases for relevant literature published from 2003 to 2023. Studies were selected based on specific exclusion criteria, and eligible articles were subjected to data extraction for subsequent subgroup analysis.
resultsFourteen studies of moderate to high quality were included. In the low-risk group, the mortality rate was significantly lower in the temsirolimus group at 0.23 (95% Cl, 0.15-0.31) compared to 0.44 (95% Cl, 0.40-0.47) in the pazopanib group. In the high-risk group, the mortality rate was 0.73 (95% Cl, 0.69-0.76) for temsirolimus and 0.67 (95% Cl, 0.64-0.71) for pazopanib.
conclusionTemsirolimus demonstrated greater efficacy in the low-risk group, while pazopanib was superior in the high-risk group for the treatment of RCC. Consideration of both efficacy and toxicity is crucial to guide drug selection for patients. TRN: CRD42024578497 (Registration date: 2024/08/21).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.